European Leukemia Trial Registry
Trial: GEPARD

More Details
Title LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDS
Scientific Title A one year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low probability of response – the GErman PAnobinostat low Risk MDS trial – GEPARD study
Short Title GEPARD
Trialgroup Deutsche MDS
Type of Trial multicentric, open-label
Disease Myelodysplastic Syndrome(MDS) Low risk and intermedia I
Age >= 18 years
Status Closed
Start of Recruitment 16.12.2009
Leader Platzbecker, Prof. Dr. med., Uwe
Contactperson

principal investigator
Platzbecker, Prof. Dr. med., Uwe
Tel: +49 (0)351 4582583
Fax: +49 (0)351 458-5362
Email: Uwe.Platzbecker@uniklinikum-dresden.de

Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Diagnostics

Zytomorphology
Hämatologisches Labor der Med. Klinik II, St. Johannes Hospital Duisburg

Cytogenetics
Labor für hämatologische Zytogenetik Göttingen

created 05.01.2010 Irene Gleske
changed 13.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org